Addex Therapeutics raised USD 2.8 million in gross proceeds through the sale of 437,869 ADSs representing 52,544,280 shares under its At-the-Market (ATM) agreement with H.C. Wainwright & Co. This capital raise extends the company's cash runway to the fourth quarter of 2027 and increases the outstanding share count to 210,292,217. Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders.

Addex Therapeutics Ltd. filed a 6-K to provide unaudited interim condensed consolidated financial statements and management's discussion and analysis of financial condition and results of operations for the period ending December 31, 2025. The filing includes a company press release. Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company.